PTC Therapeutics' Huntington's Treatment Gets FDA Fast Track Designation
PTC Therapeutics' treatment for Huntington's disease has received a fast track designation from U.S. health regulators. The biopharmaceutical company said Thursday that the Food and Drug Administration granted the designation to the PTC518 program which aims to reduce the production of mutated Huntington protein.